FDA on course for repeat oncology approvals performance
This article was originally published in Scrip
Executive Summary
Despite the relentless talk of speeding up product approvals, the US FDA is at least pretty consistent, if not marginally ahead, to repeat the same volume of oncology approvals this year as it did last.
You may also be interested in...
US is where the diagnostic partnership hub is
Partnerships between companies to develop and market diagnostic products have risen sharply over the last few years, and the lion’s share of this growth is happening in the US.